Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Accounts Payables (2023 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Accounts Payables for 6 consecutive years, with $7.2 million as the latest value for Q4 2025.

  • Quarterly Accounts Payables changed N/A to $7.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.2 million through Dec 2025, changed N/A year-over-year, with the annual reading at $7.2 million for FY2025, N/A changed from the prior year.
  • Accounts Payables for Q4 2025 was $7.2 million at Actinium Pharmaceuticals, up from $6.2 million in the prior quarter.
  • The five-year high for Accounts Payables was $9.2 million in Q2 2024, with the low at $6.2 million in Q3 2025.
  • Average Accounts Payables over 3 years is $7.4 million, with a median of $7.2 million recorded in 2025.
  • Peak annual rise in Accounts Payables hit 13.5% in 2025, while the deepest fall reached 15.94% in 2025.
  • Over 3 years, Accounts Payables stood at $8.0 million in 2023, then fell by 9.53% to $7.2 million in 2024, then grew by 0.72% to $7.2 million in 2025.
  • According to Business Quant data, Accounts Payables over the past three periods came in at $7.2 million, $6.2 million, and $7.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.